Sulfonylureas
Phase 3Small molecule
Eli LillySulfonylureas is one of 133 small molecule programs targeting Acute Pancreatitis. It is currently in Phase 3.
5
Indications
9
Total Trials
0
Active Trials
132
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Sulfonylureas
Eli LillyPhase 3
Gemzar
GGynecologic Oncology Group
Preclinical
MS Contin
Merck & Co.Preclinical
Byetta
AstraZenecaPreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
ABI-007
Bristol-Myers SquibbPreclinical
Active Comparator
ModernaPreclinical
Chemotherapy Agents
TakedaPreclinical
Concurrent Lenvatinib
TTrans Tasman Radiation Oncology Group
Preclinical
Biguanides
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Type 2 Diabetes Mellitus5 trials
Show 2 more trials
Pancreatic Cancer1 trial
Incretin-based Drugs and Pancreatic Cancer
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02475499·886,172 enrolled
Heart Failure1 trial
Incretin-based Drugs and the Risk of Heart Failure
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02456428·1,499,650 enrolled
Acute Pancreatitis1 trial
Incretin-based Drugs and Acute Pancreatitis
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02476760·1,417,914 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sulfonylureas. EMBL-EBI & Wellcome Sanger Institute.
- [4]